

DAFTAR PUSTAKA

- Aguila, J.L., Koboldt, D.C., Black, K., Chasse, R., Norton, J., Wilson, R.K., Wilson, R.K., Cruchaga, C. 2015. Alzheimer's disease: rare variants with large effect sizes. *Curr Opin Genet Dev*, 33:49–55.
- Amaral, D.G., Witter, M.P. 1989. The three-dimensional organization of the hippocampal formation: a review of anatomical data. *Neuroscience*, 31:571–591.
- Andersen, P., Bliss, T.V., Skrede, K.K. 1971. Lamellar organization of hippocampal excitatory pathways. *Exp Brain Res*, 13:222–238.
- Angelucci, F., Gelfo, F., Fiore, M., Croce, N., Mathe, A.A., Bernardini, S., Caltagirone, C. 2014. The effect of neuropeptide Y on cell survival and neurotrophin expression in in-vitro models of Alzheimer's disease. *Canadian Journal of Physiology and Pharmacology*, 92(8):621-630.
- Arendt, T., Mosch, B., Morawski, M. 2009. Neuronal Aneuploidy in Health and Disease: A Cytomic Approach to Understand the Molecular Individuality of Neurons. *Int. J. Mol. Sci*, 10(4):1609-1627.
- Balaban, C.D., O'Callaghan, J.P., Billingsley, M.L. 1988. Trimethyltin-induced neuronal damage in the rat brain: comparative studies using silver degeneration stains, immunocytochemistry and immunoassay for neurotypic and gliotypic proteins. *Neuroscience*, 26:337–361.
- Baraban, S.C. 2004. Neuropeptide Y and epilepsy: recent progress, prospects and controversies. *Neuropeptides*, 38:261–265.
- Baldock, P.A., Lee, N.J., Driessler, F., Lin, S., Allison, S., Stehrer, B., Lin, E.J., Zhang, L., Enriquez, R.F., Wong, I.P., McDonald, M.M., During, M., Pierroz, D.D., Slack, K., Shi, Y.C., Yulyaningsih, E., Aljanova, A., Little, D.G., Ferrari, S.L., Sainsbury, A., Eisman, J.A., Herzog, H. 2009. Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight. *PLoS One*, 4(12):1–5.
- Beal, M.F., Mazurek, M.F., Chattha, G.K., Svendsen, C.N., Bird, E.D., Martin, J.B. 1986. Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer's disease. *Ann. Neurol*, 20:282–288.
- Benarroch, E.E. 2009. Neuropeptide Y: its multiple effects in the CNS and potential clinical significance. *Neurology*, 72(11):1016-20.
- Berg, D. 2008. Biomarkers for the Early Detection of Parkinson's and Alzheimer's Disease. *Neurodegenerative Dis*, 5:133-136.

- Berridge, M.J., Bootman, M.D., Lipp, P. 1998. Calcium-a life and death signal. *Nature*, 395:645–648.
- Bhowmik, S., Chowdhury, S.D., Kabir, M.H., Ali, M.A. 2008. Chemical composition of some medicinal plant products of indigenous origin. *Bangladesh Vet*, 25:32-39.
- Billingsley, M.L., Yun, J., Reese, B.E., Davidson, C.E., Buck-Koehntop, B.A., Veglia, G. 2006. Functional and structural properties of stannin: roles in cellular growth, selective toxicity, and mitochondrial responses to injury. *J. Cell. Biochem*, 98:243–250.
- Bouldin T. W., Goines N. D. Bagnell C. R., and Krigman M. R. 1981. Pathogenesis of trimethyltin neuronal toxicity. *Am. J. Pathol*, 104:237-249.
- Brookmeyera, R., Elizabeth, Johnsona., Kathryn Ziegler-Grahamb., H. Michael Arrigh. 2007. Forecasting the global burden of Alzheimer's disease. *Alzheimer's & Dementia*, 3:186–191.
- Brown A. W., Aldridge W. N., Street B. W., and Verschoyle R. D. 1979. The behavioral and neuropathologic sequelae of intoxication by trimethyltin compounds in the rat. *Am. J. Pathol*, 97:59-82.
- Buckmaster, P.S., Wenzel, H.J., Kunkel, D.D., Schwartzkroin, P.A. 1996. Axon arbors and synaptic connections of hippocampal mossy cells in the rat in vivo. *J Comp Neurol*, 366:271–292.
- Burwell, R.D. 2000. The parahippocampal region: corticocortical connectivity. *AnnNY Acad Sci*, 911:25–42.
- Cajal, S.R.Y. 1995. *Histology of the Nervous System of Man and Vertebrates*. Translated by Neely Swanson and Larry W. Swanson. Oxford university Press: New York.
- Ceccariglia, S., D'Altocolle, A., Del Fa, A., Pizzolante, F., Caccia, E., Michetti, F., Gangitano, C. 2011. Cathepsin D plays a crucial role in the trimethyltin-induced hippocampal neurodegeneration process. *Neuroscience*, 174:160–170.
- Chang, L.W., Dyer, R.S. 1983. A time course study of trimethyltin induced neuropathology in rats. *Neurobehav. Toxicol. Teratol*, 5:443–459.
- Chan-Palay, V., Lang, W., Haesler, U., Kohler, C., Yasargil, G. 1986. Distribution of altered hippocampal neurons and axons immunoreactive with antisera against neuropeptide Y in Alzheimer's-type dementia. *J. Comp. Neurol*, 248:376–394.

- Clark, J.T., Kalra, P.S., Crowley, W.R., Kalra, S.P. 1984. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. *Endocrinology*, 115(1):427-9.
- Croce, N., Dinallo, V., Ricci, V., Federici, G., Caltagirone, C., Bernardini, S., Angelucci, F. 2011. Neuroprotective effect of neuropeptide Y against beta-amyloid 25–35 toxicity in SH-SY5Y neuroblastoma cells is associated with increased neurotrophin production. *Neurodegener*, 8:300–309.
- Croce, N., Ciotti, M.T., Gelfo, F., Cortelli, S., Federici, G., Caltagirone, C., Bernardini, S., Angelucci, F. 2012. Neuropeptide Y protect rat cortical neurons against β -amyloid toxicity and re-establishes synthesis and release of nerve growth factor. *ACS Chem. Neurosci*, 3:312–318.
- Davidson, C.E., Reese, B.E., Billingsley, M.L., Yun, J.K. 2004. Stannin, a protein that localizes to the mitochondria and sensitizes NIH-3T3 cells to trimethyltin and dimethyltin toxicity. *Mol. Pharmacol*, 66:855–863.
- Davidson, C.E., Reese, B.E., Billingsley, M.L., Yun, J.K. 2005. The protein stannin binds 14-3-3zeta and modulates mitogen-activated protein kinase signaling. *Brain Res. Mol. Brain Res*, 138:256–263.
- Davies, C.A., Morroll, D.R., Prinja, D., Mann, D.M., Gibbs, A. A. 1990. Quantitative assessment of somatostatin-like and neuropeptide Y-like immunostained cells in the frontal and temporal cortex of patients with Alzheimer's disease. *J Neurol Sci*, 96:59–73.
- Decressac, M., Prestoz, L., Veran, J., Cantereau, A., Jaber, M., Gaillard, A. 2009. Neuropeptide Y stimulates proliferation, migration and differentiation of neural precursors from the subventricular zone in adult mice. *Neurobiol. Dis*, 34:441–449.
- Decressac, M., Barker, R.A. 2012. Neuropeptide Y and its role in CNS disease and repair. *Exp. Neurol*, 238(2):265–272.
- Deshmukh, S.S., Yoganarasimha, D., Voicu, H., Knierim, J.J. 2010. Theta modulation in the medial and the lateral entorhinal cortices. *J Neurophysiol*, 104:994–1006.
- Deshmukh, S.S., Knierim, J.J. 2011. Representation of nonspatial and spatial information in the lateral entorhinal cortex. *Front Behav Neurosci*, 5:69.
- Devi, P.U., Ganasoundari, A. 1999. Modulation of glutathione and antioxidant enzymes by *Ocimum sanctum* and its role in protection against radiation injury. *Indian J Exp Biol*, 37: 262-268.
- Diez, M., Koistinaho, J., Kahn, K., Games, D., Hokfelt, T. 2000. Neuropeptides in hippocampus and cortex in transgenic mice

overexpressing V717F beta-amyloid precursor protein—initial observations. *Neuroscience*, 100:259–286.

- Dokania, M., Kishore, K., Sharma, P.K. 2011. Effect of *Ocimum sanctum* extract on sodium nitrite-induced experimental amnesia in mice. *Thai J. Pharm. Sci*, 35:123-130.
- Dumont, Y., Jaxques, D., Bouchard, P., Quirion, R. 1998. Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains. *J. Comp. Neurol*, 402(3):372-84.
- Earley, B., Burke, M., Leonard, B.E. 1992. Behavioural, biochemical and histological effects of trimethyltin (TMT) induced brain damage in the rat. *Neurochem Int*, 21(3):351-66.
- Edvinsson, L., Minthon, L., Ekman, R., Gustafson, L., 1993. Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration. *Dementia*, 4:67–171.
- Eriksson, P.S., Perfilieva, E., Bjork-Eriksson, Y., Alborn, A.M., Nordborg, C., Peterson, D.A., Gage, H. 1998. Neurogenesis in the adult human hippocampus. *Nat Med*, 4(11):1313-7.
- Ferri, C.P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., Jorm, A., Mathers, C., Menezes, P.R., Rimmer, E., Sczufca, M. 2005. Global prevalence of dementia: a Delphi consensus study. *The Lancet*, 366(9503):2112–2117.
- Gandhi, S., Wood-Kaczmar, A., Yao, Z., Plun-Favreau, H., Deas, E., Klupsch, K., Downward, J., Latchman, D.S., Tabrizi, S.J., Wood, N.W., Duchen, M.R., Abramov, A.Y. 2009. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. *Mol. Cell*, 33:627–638.
- Gandhi, R., Chauhan, B., Jadeja, G. 2016. Effect of *Ocimum Sanctum* (Tulsi) Powder on Hyperglycemic Patient. *Indian J Appl Res*, 6.
- Geloso, M.C., Corvino, .V., Michetti, F. 2011. Trimethyltin-induced hippocampal degeneration as a tool to investigate neurodegenerative processes. *Neurochem Int*, 58(7):729-38.
- Giridharan., Vayalanellore, V., dan Thandavarayan, R. A. 2011. *Ocimum sanctum* Linn. Leaf Extracts Inhibit Acetylcholinesterase and Improve Cognition in Rats with Experimentally Induced Dementia. *Journal of Medicinal Food* 14(9): 912–919. Gray WP. 2008. Neuropeptide Y signalling on

- hippocampal stem cells in health and disease. *Mol Cell Endocrinol*, 288:52–62.
- Glabe, C. C. 2005. Amyloid accumulation and pathogenesis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar A β . *Subcell Biochem*, 38:167-77.
- Gray, W.P. 2008. Neuropeptide Y signalling on hippocampal stem cells in health and disease. *Mol Cell Endocrinol*, 288:52–62.
- Griffin, W.S.T. 2006. Inflammation and neurodegenerative disease. *Am. J. Clin. Nutr*, 83:472-474.
- Hargreaves, E.L., Rao, G., Lee, I., Knierim, J.J. 2005. Major dissociation between medial and lateral entorhinal input to dorsal hippocampus. *Science*, 308:1792–1794.
- Harry, G.J., Lefebvre d'Hellencourt, C. 2003. Dentate gyrus: alterations that occur with hippocampal injury. *Neurotoxicology*, 24:343–356.
- Hawley, W. R., Witty, C. F., Daniel, J. M., dan Dohanich, G. P. 2015. Choline Acetyltransferase in The Hippocampus is Associated with Learning Strategy Preference in Adult Male Rats. *Behavioural Brain Research*, 289:118–124.
- Henriksen, E.J., Colgin, L.L., Barnes, C.A., Witter, M.P., Moser, M.B., Moser, E.I. 2010. Spatial representation along the proximodistal axis of CA1. *Neuron*, 68:127–137.
- Hernández, S., Gilabert-Juan, J., Blasco-Ibáñez, J.M., Crespo, C., Nácher, J., Varea, E. 2012. Altered expression of neuropeptides in the primary somatosensory cortex of the Down syndrome model Ts65Dn. *Neuropeptides*, 46(1):29–37.
- Hirsch, D and Zukowska, Z. 2012. NPY and stress 30 years later: the peripheral view. *Cell. Mol. Neurobiol*, 32:645-659.
- Holzer, P., Reichmann, F., Farzi, A. 2012. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. *Neuropeptides*, 46(6):261–274.
- Hunsaker, MR., Rosenberg, J.S., Kesner, R.P. 2008. The role of the dentate gyrus, CA3a, b, and CA3c for detecting spatial and environmental novelty. *Hippocampus*, 18:1064–1073.
- Joshi, H., dan Parle, M. 2006. Evaluation of Nootropic Potential of *Ocimum sanctum* Linn in Mice. *Indian Journal of Experimental Biology*, 44:133-136.

- Joushi, S., Salmani, M.E. 2017. Effect of eugenol on lithium-pilocarpine model of epilepsy: behavioral, histological, and molecular changes. *Iran J Basic Med Sci*, 20:745-752.
- Kaler, S., Dhar, P., Bhattacharya, A., Mehra, R.D. 2013. Preliminary Morphological and Immunohistochemical Changes in Rat Hippocampus Following Postnatal Exposure to Sodium Arsenite. *Toxicol Int*, 20(2):160–169.
- Karl, T., Herzog, H. 2007. Behavioral profiling of NPY in aggression and neuropsychiatric diseases. *Peptides*, 28:326–333.
- Kask, A., Harro, J., von Horsten S., Redrobe, J.P., Dumont, Y., Quirion, R. 2002. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. *Neurosci Biobehav Rev*, 26(3):259–283.
- Klüver, H., Barrera, E. 1953. A method for the combined staining of cells and fibers in the central nervous system. *J Neuropathol Exp Neurol*, 12:400–403.
- Kovacs, G.G. 2016. Molecular Pathological Classification of Neurodegenerative Disease: Turning towards Precision Medicine. *Int. J. Mol. Sci*, 17:189.
- Kumar, R. S., Rao, M. S., Nayak S., dan Saresh N. N. 2007. Effect Of *Ocimum sanctum* (Linn) Extraction on Restraint Stress Induced Behavioral Deficits in Male Wistar Rats. *Pharmacologyonline*, 3:394-404.
- Kusindarta, D. L., Wihadmadyatami, H., dan Haryanto, A. 2016. *Ocimum sanctum* Linn. Stimulate the Expression of Choline Acetyltransferase on The Human Cerebral Microvascular Endothelial Cells. *Vet World*, 9(12):1348–1354.
- Kusindarta, D. L., Wihadmadyatami, H., dan Haryanto, A. 2018^a. The analysis of hippocampus neuronal density (CA1 and CA3) after *Ocimum sanctum* ethanolic extract treatment on the young adulthood and middle age rat model. *Vet World*, 11(2):135–140.
- Kusindarta, D. L., Wihadmadyatami, H., Jadi, A.R., Karnati, S., Lochnit, G., Hening, P., Haryanto, A., Auriva, M.B., Purwaningrum, M. 2018^b. Ethanolic extract *Ocimum sanctum*. Enhances cognitive ability from young adulthood to middle aged mediated by increasing choline acetyl transferase activity in rat model. *Vet Science*, 431-438.
- LaFerla, F.M. 2002. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. *Nat. Rev. Neurosci*, 3:862–872.
- Li, X.G., Somogyi, P., Ylinen, A., Buzsaki, G. 1994. The hippocampal CA3 network: an in vivo intracellular labeling study. *J Comp Neurol*, 339:181–208.

- Malva, J.O., Xapelli, S., Baptista, S., Valero, J., Agasse, F., Ferreira, R., Silva, A.P. 2012. Multifaces of neuropeptide Y in the brain-neuroprotection, neurogenesis and neuroinflammation. *Neuropeptides*, 46:299–308.
- Martin, J.H. 2003. *Neuroanatomy: Text and Atlas*. Third edition. The McGraw-Hill Companies, Inc.
- Masliukov, P.M., Konovalov, V.V., Emanuilov, A.I., Nozdrachev, A.D. 2012. Development of neuropeptide Y-containing neurons in sympathetic ganglia of rats. *Neuropeptides*, 46(6):345–352.
- Mason, V.L. 2015. Alzheimer's Association International Conference on Alzheimer's Disease 2015. *Drugs of Today*, 51(7):447-452.
- Mathern, G.W., Babb, T.L., Pretorius, J.K., Leite, J.P. 1995. Reactive synaptogenesis and neuron densities for neuropeptide Y, somatostatin, and glutamate decarboxylase immunoreactivity in the epileptogenic human fascia dentata. *J Neurosci*, 15:3990–4004
- Matsson, M.P. 2000. Apoptosis in Neurodegenerative Disorder. *Nat. Rev. Mol. Cell Biol*, 1:120-129.
- Mayeux, R and Yaakov Stern. 2012. Epidemiology of Alzheimer Disease. *Cold Spring Harb Perspect Med*, 2:6239.
- Menal, M., Jorba, I., Torres, M., Montserrat, J., Gozal, D., Colell A., Ripoll, G., Navajas, D., Almendros, I., Farre, R. 2018. Alzheimer's Disease Mutant Mice Exhibit Reduced Brain Tissue Stiffness Compared to Wild-type Mice in both Normoxia and following Intermittent Hypoxia Mimicking Sleep Apnea. *Front Neurol*, 9:1.
- Minthon, L., Edvinsson, L., Ekman, R., Gustafson, L. 1990. Neuropeptide levels in Alzheimer's disease and dementia with frontotemporal degeneration. *J. Neural Transm. Suppl*, 30:57–67.
- Naber, P.A., Lopes da Silva, F.H., Witter, M.P. 2001. Reciprocal connections between the entorhinal cortex and hippocampal fields CA1 and the subiculum are in register with the projections from CA1 to the subiculum. *Hippocampus*, 11:99–104.
- Nilsberth, C., Kostyszyn, B., Luthman, J. 2002. Changes in APP, PS1 and other factors related to Alzheimer's disease pathophysiology after trimethyltin-induced brain lesion in the rat. *Neurotox. Res*, 4:625–636.
- Noe, F., Nissinen, J., Pitkanen, A., Gobbi, M., Sperk, G., Doring M., Vezzani, A. 2007. Gene therapy in epilepsy: the focus on NPY. *Peptides*, 28:377–383.

- O'Callagan, J.P., Niedwiecke, D.M., Means, J.C. 1989. Variations in the neurotoxic potency of trimethyltin. *Brain Res. Bull*, 2:637–642.
- O'Reilley, R. C., dan McClelland, J. L. 1994. Hippocampal Conjunctive Encoding, Storage, and Recall: Avoiding a Trade-Off. *Hippocampus*, 4(6):661-682.
- Pappas, B.A., Bayley, P.J., Bui, B.K., Hansen, L.A., Thal, L.J. 2000. Choline acetyltransferase activity and cognitive domain scores of Alzheimer's patients. *Neurobiol Aging*, 21:11-17.
- Perretta, G., Righi, F.R., Gozzo, S. 1993. Neuropathological and behavioral toxicology of trimethyltin exposure. *Ann. Ist. Super. Sanita*, 29:167–174.
- Prakash P, Gupta N. 2005. Therapeutic uses of *Ocimum sanctum* Linn (Tulsi) with a note on eugenol and its pharmacological actions: a short review. *Indian J Physiol Pharmacol*, 49:125-131.
- Pratico, D. 2008. Evidence of oxidative stress in Alzheimer's disease ` brain and antioxidant therapy: lights and shadows. *Annals of the New York Academy of Sciences*, 1147:70–78.
- Raghavendra M, Maiti R, Kumar S, Acharya SB. 2009. Role of *Ocimum sanctum* in the experimental model of Alzheimer's disease in rats. *International Journal of Green Pharmacy*, 3(1):6.
- Ramos, B., Baglietto-Vargas, D., del Rio, J.C. Moreno-Gonzales, I., Santa-Maria, C., Jimenez, S., Caballero, C., Lopez-Tellez, J.F., Khan, Z.U., Ruano, D., Gutierrez, A., Vitorica, J. 2006. Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease. *Neurobiol Aging*, 27:1658–1672.
- Rancillac, A., Laine, J., Perrenoud, Q., Geoffroy, H., Ferezou, I., Vitalis, T., Rossier, J. 2010. Degenerative abnormalities in transgenic neocortical neuropeptide Y interneurons expressing tau-green fluorescent protein. *J. Neurosci. Res*, 88:487–499.
- Rashid, A.N.M., Azam, MD. M., Dash, B.K., Hafiz, F.B., Sen, M.K. 2013. Ethnomedicobotanical Study on *Ocimum Santum* L. (Tulsi). *Mintage journal of Pharmaceutical and Medical Sciences*, 37-42.
- Redrobe, J.P., Dumont, Y., St-Pierre, J.A., Quirion, R. 1999. Multiple receptors for neuropeptide Y in the hippocampus: putative roles in seizures and cognition. *Brain Research*, 848:153–166.
- Redrobe, J.P., Dumont, Y., Herzog, H., Quirion, R. 2003. Characterization of Neuropeptide Y, Y2 Receptor Knockout Mice in Two Animal Models of Learning and Memory Processing. *Journal of Molecular Neuroscience*, 22:159–166.

- Rose, J.B., Crews, L., Rockenstein, E., Adame, A., Mante, M., Hersh, L.B., Gage, F.H., Spencer, B., Potkar, R., Marr, R.A., Masliah, E. 2009. Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease. *J. Neurosci*, 29:1115–1125.
- Samson, J., Sheeladevi, R., dan Ravindran, R. 2007. Oxidative Stress in Brain and Antioxidant Activity of *Ocimum sanctum* in Noise Exposure. *NeuroToxicology*, 28:679–685.
- Sembulingam, K., Prema, Sembulingam, Namasivayam, A. 2005. Effect of *Ocimum santum* Linn on The Canges in Central Cholinergic System Induced by Acute Noise Stress. *J Ethnopharmacol*, 96:477-482.
- Sethi J, Sood S, Seth S, Talwar A. 2004. Evaluation of hypoglycemic and antioxidant effect of *Ocimum sanctum*. *Indian J Clin Biochem*, 19:152-155.
- Silva, A.P., Cavadas, C., Grouzmann, E. 2002. Neuropeptide Y and its receptors as potential therapeutic drug targets. *Clin Chim Acta*, 326:3–25.
- Silva, A.P., Xapelli, S., Grouzmann, E., Cavadas, C. 2005. The putative neuroprotective role of neuropeptide Y in the central nervous system. *Curr Drug Targets CNS Neurol Disord*, 4:331–347.
- Singh, N., Verma, P., Pandey, B.R., Bhalla, M. 2012. Therapeutic potential of *Ocimum sanctum* in prevention and treatment of cancer and exposure to radiation: An overview. *Int J Pharmaceut Sci Drug Res*, 4:97-104.
- Sperk, G., Hamilton, T., Colmers, W.F. 2007. Neuropeptide Y in the dentate gyrus. *Prog Brain Res*, 163:285–297.
- Steward, O., Scoville, S.A. 1976. Cells of origin of entorhinal cortical afferents to the hippocampus and fascia dentata of the rat. *J Comp Neurol*, 169:347–370.
- Tasan, R.O., Verma, D., Wood, J., Lach, G., Horner, B., de Lima, T.C.M., Herzog, H., Sperk, G. 2016. The role of Neuropeptide Y in fear conditioning and extinction. *Neuropeptides*, 55:111–126.
- Tatemoto, K. 1982. Neuropeptide Y: complete amino acid sequence of the brain peptide. *Proc Natl Acad Sci U S A*, 79(18):5485–5489.
- Thiriet, N., Agasse, F., Nicoleau, C., Guegan, C., Vallette, F., Cadet, J.L., Jaber, M., Malva, J.O., Coronas, V. 2011. NPY promotes chemokinesis and neurogenesis in the rat subventricular zone. *J. Neurochem*, 116:1018–1027

- Toggas, S.M., Krady, J.K., Billingsley, M.L. 1992. Molecular neurotoxicology of trimethyltin: identification of stannin, a novel protein expressed in trimethyltin-sensitive cells. *Mol. Pharmacol*, 42:44–56.
- Tramatola, A., Triani, F., Di Domenico, F., Barone, E., Cai, J., Klein, J.B., Perluigi, M., Allan, B. D. 2018. Poly-ubiquitin profile in Alzheimer disease brain. *Neurobiol Dis*, 118:129-141.
- Travaglia, A., Bisaz, R., Cruz, E., dan Alberini, C.M. 2016. Developmental Changes in Plasticity, Synaptic, Glia and Connectivity Protein Levels in Rat Dorsal Hippocampus. *Neurobiology of Learning and Memory*, 135:125–138.
- Tsunashima, K., Sadamatsu, M., Takahashi, Y., Kato, N., Sperk, G. 1998. Trimethyltin intoxication induces marked changes in neuropeptide expression in the rat hippocampus. *Synapse*, 29:333–342.
- USDA. 2013. Classification for Kingdom Plantae Down to Genus *Ocimum* L. United States Departemen of Agriculture. <http://www.plants.usda.gov/java/ClassificationServlet?source=display&classid=OCIMU>. Diakses 12 Januari 2018 08.09 WIB.
- van Wamelen, D.J., Aziz, N.A., Anink, J.J., Roos, R.A., Swaab, D.F. 2013. Neuropeptide alterations in the infundibular nucleus of Huntington’s disease patients. *J. Neuroendocrinol*, 25(2):198–205.
- Vidhani, S.I, Vyas, V.G., Parmar, H.J., Bhalani, V.M., Hassan, M.M., Gaber, A., Golakiya, B.A. 2016. Evaluation of Some Chemical Composition, Minerals Fatty Acid Profiles, antioxidant and Antimicrobial Activities of Tulsi (*Ocimum sanctum*) from India. *Am J Food Sci Technol*, 4:52-57.
- WHO. 2015. Dementia. <http://www.who.int/mediacentre/factsheets>. Diakses pada 12 Januari 2018 pukul 08.09 WIB.
- Wilcock, D.M., Lewis, M.R., Van Nostrand, W.E., Davis, J., Previti, M.L., Gharkholonarehe, N., Vitek, M.P., Colton, C.A. 2008. Progression of amyloid pathology to Alzheimer’s disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. *J. Neurosci*, 28:1537–1545.
- Wu, Y.F and Li, S.B. 2005. Neuropeptide Y expression in mouse hippocampus and its role in neuronal excitotoxicity. *Acta Pharmacol Sin*, 26(1):63-8.
- Xapelli, S., Agasse, F., Ferreira, R., Silva, A.P., Malva, J.O. 2006. Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide. *Recent Pat CNS Drug Discov*, 1:315–324.

- Yoganarasimha, D., Rao, G., Knierim, J.J. 2011. Lateral entorhinal neurons are not spatially selective in cue-rich environments. *Hippocampus*, 21:1363–1374.
- Zhou, Z., Zhu, G., Hariri, A.R., Enoch, M.A., Scott, D., Sinha, R., Virkkunen, M, Mash, D.C, Lipsky, R.H, Hu, X.Z, Hodgkinson, C.A, Xu, K., Buzas, B, Yuan, Q, Shen, P.H, Ferrell, R.E, Manuck, S.B, Brown, S.M., Hauger, R.L, Stohler, C.S, Zubieta, J.K., Goldman, D. 2008. Genetic variation in human NPY expression affects stress response and emotion. *Nature*, 452:997–1001.